To determine, in a prospective, multicentre setting, the prevalence of fluoroquinolone-resistant (FQ-R) and extendedspectrum b-lactamase (ESBL)-producing Escherichia coli (E. coli) strains in men undergoing transrectal ultrasonography-guided prostate biopsy (TRUS-Bx) in Finland; and to survey the associated risk factors for having the previously mentioned strains.
Objectives
To determine, in a prospective, multicentre setting, the prevalence of fluoroquinolone-resistant (FQ-R) and extendedspectrum b-lactamase (ESBL)-producing Escherichia coli (E. coli) strains in men undergoing transrectal ultrasonography-guided prostate biopsy (TRUS-Bx) in Finland; and to survey the associated risk factors for having the previously mentioned strains.
Patients and Methods
This is a substudy of the trial investigating the role of magnetic resonance imaging (MRI) in prostate cancer diagnosis (Improved Prostate Cancer DiagnosisCombination of Magnetic Resonance Imaging Targeted Biopsies and Biomarkers Multi-institutional Study [multi-IMPROD], NCT02241122). In all, 359 patients from four study centres were recruited to this prospective study. After having signed the informed consent form, these men with suspicion of prostate cancer completed a detailed questionnaire on their medical, smoking, and travelling history, as well as their recent use of antibiotics. After the biparametric MRI scan, TRUS-Bx was taken and a rectal swab sample was collected and cultured for determining the antimicrobial susceptibility profile of E. coli strains. The potential risk factors for having FQ-R or third-generation cephalosporin-resistant (3GC-R) E. coli strains were analysed using univariate and multivariate logistic regression analysis.
Results
The percentage of FQ-R and 3GC-R E. coli strains amongst the study population was 13% and 8%, respectively. Amongst patients having E. coli strains, the rate of FQ-R and 3GC-R strains was 14% and 8%, respectively. Of the 3GC-R E. coli strains, 62% proved to be ESBL-producers and 88% were also FQ-R. In multivariate analysis, international travel during the preceding year significantly increased the risk of having a FQ-R E. coli strain (odds ratio [OR] 3.592, P = 0.001) and, unexpectedly, use of antibiotics during the previous year significantly decreased this risk (OR 0.442, P = 0.035). No significant risk factors for having 3GC-R E. coli were identified.
Introduction
TRUS-guided prostate biopsy (TRUS-Bx) is one of the most common urological procedures. It is used as a diagnostic and surveillance tool in active surveillance of prostate cancer [1] . The biopsies are commonly taken via a transrectal approach, although it has been proposed that a transperineal approach may be a better alternative in certain cases [2] . Antibiotic prophylaxis, most commonly fluoroquinolones (FQs), are usually administered before biopsy [1] .
TRUS-Bx is generally a well-tolerated procedure but complications are not uncommon either. According to recent studies, lower urinary tract infections after TRUS-Bx occur in 1-17.5% [3] and infectious complications requiring hospitalisation in 0-6.3% of the cases [4] . Sepsis and bacteraemia are the most serious complications after TRUSBx, thus their incidence varies amongst studies between 0.62% and 3.06% [5] [6] [7] [8] [9] . Antibiotic prophylaxis before a TRUS-Bx procedure is shown to be effective against infectious complications [10, 11] . FQ-based antibiotics are recommended due to their good bioavailability after oral administration, effective penetration into the prostatic tissue, and wide effect spectrum against gram-negative pathogens. Although FQs are the most studied group of antibiotics in TRUS-Bx prophylaxis, their superiority to other antibiotics against post-TRUS-Bx infectious complications has remained unclear [12] .
The rate of FQ-resistant (FQ-R) pathogens [13, 14] , post-TRUS-Bx infectious complications [3, 15, 16] , as well as septic and bacteraemic complications [5, 17] , has increased during recent years. FQ resistance in blood and urine isolates are also over-represented in patients with post-TRUS-Bx infectious complications compared to patients without biopsyrelated complications [18, 19] . Escherichia coli (E. coli) is by far the most common FQ-R pathogen and the most common pathogen causing infections after TRUS-Bx [19, 20] . It has been suggested that the increased rate of post-TRUS-Bx infectious complications is a consequence of the increased rate of FQ resistance [3] [4] [5] [6] 21] . Therefore, the contemporary practice of preventing infectious complications should be reassessed.
Although less common than FQ resistance, the rate of extended-spectrum b-lactamases (ESBL)-producing pathogens has also increased during the last decade [13] . The most common ESBL-producing pathogen is E. coli. ESBLs are a heterogeneous family of plasmid-mediated enzymes that inactivate and confer resistance to most b-lactam antibiotics, including penicillins and cephalosporins. In addition, ESBLproducing pathogens show greater resistance to FQs than the average [22] . Cephalosporins are commonly used in first-line parenteral antimicrobial therapy in community-acquired infections, which makes the increasing rate of ESBLproducing pathogens a major healthcare problem.
The objective of the present study was to determine, in a prospective, multicentre setting, the current rate of FQ-R and ESBL-producing E. coli strains in men undergoing TRUS-Bx procedures in Finland, and to survey the associated risk factors for having these resistant strains. After signing the informed consent, the patients underwent bi-parametric MRI followed by TRUS-Bx. Before the TRUSBx, the patients completed a detailed questionnaire about their medical, smoking, and travel history, and their recent use of antibiotics. Different antibiotic regimens were analysed as one category because the study patients rarely recalled the name of the antibiotic used. During the TRUS-Bx procedure, faecal samples were collected with sterile rectal swabs (Copan FLOQSwab TM , Copan Diagnostics Inc., Murrieta, CA, USA). The TRUS-Bx included systematic 12 cores in each case and two additional targeted cores for each MRI target lesion (one to two target lesions per patient, i.e. two to four targeted biopsies). Faecal swabs were sent to the medical microbiology laboratory for culturing. Samples were directly cultured on a CHROMagar TM Orientation plate (CHROMagar, Paris, France). A ciprofloxacin disc (5 lg, Oxoid, Thermo Scientific, Helsinki, Finland) was added on top of the plate to select the patient's most resistant bacteria. The plates were incubated over night at +35°C. The following day, the most resistant E. coli strain was selected for pure culture, i.e. pink or dark rose colony nearest to the ciprofloxacin disc. Antimicrobial susceptibility testing of E. coli isolates was performed with the disc diffusion method using Oxoid susceptibility discs 204 © 2018 The Authors BJU International © 2018 BJU International (Thermo Scientific). Susceptibility was tested against ampicillin (10 lg), amoxicillin-clavulanic acid (30 lg), mecillinam (10 lg), cefoxitin (30 lg), cefotaxime (5 lg), ceftazidime (10 lg), meropenem (10 lg), ciprofloxacin (5 lg), gentamicin (10 lg), nitrofurantoin (100 lg), trimethoprim (5 lg), and trimethoprim-sulphamethoxazole (25 lg) on Mueller-Hinton agar (Oxoid; Thermo Scientific) plates according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines (http://www.euca st.org/ast_of_bacteria/). Ciprofloxacin-resistant strains (inhibition zone <24 mm) were re-tested and resistance to FQs was confirmed with nalidixic acid (30 lg), levofloxacin (5 lg) and pefloxacin (5 lg) discs.
Patients and Methods
Isolates showing reduced susceptibility to cefotaxime and ceftazidime (inhibition zone <21 and <22 mm, respectively) were tested for ESBL production with the combination disc test (Rosco ESBL and AmpC confirmation Kit, Rosco, Denmark). Bacterial strains were incubated with cefotaxime and cefotaxime-clavulanic acid, as well as ceftazidime and ceftazidime-clavulanic acid discs. If the inhibition zone around the antimicrobial disc with clavulanic acid was ≥5 mm greater than the inhibition zone around the antimicrobial disc without clavulanic acid, the strain was determined to be an ESBL producer. In this study, E. coli strains that were third-generation cephalosporin-resistant (3GC-R) were used instead of ESBL-production in all analysis.
Before collecting the rectal swab samples and the TRUS-Bx procedure, antibiotic prophylaxis was administered according to the guidelines of each research centre.
EUCAST guidelines for determining antimicrobial susceptibility are updated annually. In the risk factor analysis, the most recent EUCAST 2017 clinical breakpoint criteria were used. As the criteria for defining FQ-R E. coli strains changed considerably in the latest EUCAST update [23] , we analysed FQ-resistance rates in E. coli strains also according to the prior EUCAST criteria. The definition of 3GC-resistance of E. coli did not change during the study period.
The statistical analyses were performed using the IBM Statistical Package for the Social Sciences (SPSS ) and categorical variables as number (%). Univariate and multivariate logistic regression analysis was used to determine potential risk factors for harbouring FQ-R or 3GC-R E. coli strains in rectal swab samples. The results are presented as odds ratios (ORs) with 95% CIs. International travel during the last year was combined as one variable in the final analysis. Other potential risk factors were chosen based on earlier studies and clinical experience. The patients without E. coli growth in the rectal swab sample were analysed as FQ-susceptible E. coli strains, whilst FQ-R and FQ-intermediate resistant E. coli strains were analysed together as one variant. Finally, the patients were divided into nine categories based on their travel history to various regions during the preceding year and the rate of FQ-R E. coli in their rectal swab samples. The rates of FQ-R E. coli were determined separately for each of the travel destination categories. Statistical significance was set at P ≤ 0.05 in the statistical analyses.
The study was conducted in compliance with the current revision of Declaration of Helsinki guiding physicians and medical research involving human subjects (59th World Medical Association General Assembly, Seoul, Korea, 2008). Before commencement of the study, the study protocol, the patient information sheet, and the informed consent form were approved by the Ethics Committee of the Hospital District of Southwest Finland.
Results
The collection of patient data is shown in Fig. 1 . A total of 359 patients from four study centres were recruited to the study. Microbiological samples were available from 317 patients. In all, 62 patients were excluded from the initial study population due to missing questionnaires or microbiological samples, thus 297 patients were included in the risk factor analysis.
Study patient characteristics are presented in Table 1 . The mean age was 64 years and the mean prostate size was 45 mL. A total of 55% of the patients had travelled internationally during the preceding year.
The results of the rectal swab cultures are presented in Table 2 . According to EUCAST 2017 criteria, the rates of FQ-R and 3GC-R E. coli strains at the patient level were 13% and 8%, respectively, whereas the rates of FQ-R and 3GC-R strains amongst patients having E. coli strain were 14% and 8%, respectively. Of patients with an 3GC-R E. coli strain, 13/ 21 (62%) were ESBL-producers and 21/24 (88%) were FQ-R. Differences in the FQ-R rates between patients from different study centres were notable in our study, with the highest rates in the Helsinki (18%) and the lowest in the Pori (5%) study centre.
The risk factor analysis for antibiotic resistance is presented in Tables 3 and 4 . In univariate analysis, smoking, diabetes, recent use of antibiotics, and age did not have a statistically significant influence on the risk of having FQ-R E. coli strains. In univariate and multivariate analysis, any international travel during the preceding year significantly increased the risk of colonisation with FQ-R E. coli strains (OR 3.592, P = 0.001). Surprisingly, in multivariate analysis, recent (undefined) antibiotic therapy during the preceding year reduced the risk of having FQ-R E. coli strains (OR 0.442, P = 0.035). None of the risk factors had a significant influence on the 3GC-R rates in E. coli strains in univariate or multivariate analysis. Although no significant risk factors were found, we identified a trend of increasing risk of 3GC-R E. coli strains in patients with an international travel and smoking history.
The rate of patients with FQ-R E. coli strains in the rectal swab sample was compared to the patients' travel history during the preceding year. The results are presented in Fig. 2 . Travelling, especially to Asia or Japan, considerably increased the risk of a FQ-R E. coli strain in the rectal swab sample.
Discussion
In our present prospective study, we found FQ-R strains in 13% and 3GC-R E. coli strains in 8% in the pre-TRUS-Bx rectal swab samples of the study population. Of the 3GC-R E. coli strains, 62% proved to be ESBL-producers. In multivariate risk factor analysis, international travel during the preceding year significantly increased the risk of having a FQ-R E. coli strain. Surprisingly, the use of any antibiotics during the preceding year decreased the risk. We did not find any significant risk factors for having 3GC-R E. coli. The details of TRUS-Bx-related complications in the present study are reported elsewhere [24] . Previously, it has been reported that FQ-R coliforms can be found in 10.6-40.4% [18, [25] [26] [27] and ESBL-producing organisms in 1.3-41.0% of pre-TRUS-Bx rectal swab cultures [19, 26, 27] . In these studies, E. coli was the most common FQ-R and ESBL-producing gram-negative organism. In addition, it has been reported that E. coli is the most common pathogen causing post-TRUS-Bx infections [20] . The wide range in rates of FQ-R and ESBL-producing microorganisms may have several explanations. The variation may be caused by territorial differences in antimicrobial susceptibility or the timing of the publications. As these studies were published during the last 7 years, the globally increasing trend of antimicrobial resistance could also slightly affect the results [13, 14] . Finally, the definitions and protocols of measuring antimicrobial susceptibility vary between the studies.
In the present study, international travel was clearly associated with the risk of having a FQ-R E. coli strain. We also identified a similar trend for the 3GC-R E. coli strains. The patients' travelling history and FQ-R E. coli in the rectal swab sample also correlated quite well with prevailing global FQ-resistance rates [13] . The correlation between international travel and FQ resistance has also been noted in previous studies. Kennedy et al. [28] analysed perianal and rectal swab samples from patients before and after international travel. Colonisation with ciprofloxacin-resistant E. coli increased from 3.9% to 33.3% and the ESBL rate increased from 2.0% to 21.6% after travelling. Those colonised patients had more likely taken antibiotics during their travel than non-colonised patients. However, travelling remained an independent risk factor regardless of the patients' use of antibiotics. International travel and travelling to regions with a high prevalence of antimicrobial resistance in particular, appears an indisputable risk factor for having FQ-R or ESBL-producing E. coli strains.
Variation in resistance rates between the four study centres in Finland were remarkable, especially the high rate of FQ-R and 3GC-R strains in the Helsinki study centre. This finding may also relate presumably to different travelling habits and a more international population in the capital city of Finland. Surprisingly, our present results indicate that the use of antibiotics during the preceding year reduced the risk of having a FQ-R E. coli strain. Although, Kamei et al. [29] and Duplessis et al. [26] found no difference in FQ-R between study groups with prior usage of FQ or other antibiotic therapy during the preceding 3 months and 1 year [26, 29] , there are several reports arguing otherwise. Taylor et al. [19] presented an increased risk for FQ-R coliforms in patients with ciprofloxacin usage during the last 3 months. In addition, Steensels et al. [5] found an increased risk of having FQ-R E. coli strains in patients with FQ usage during the 6 months before TRUS-Bx. Tsu et al. [27] reported that antimicrobial usage during the preceding 5 years is a significant risk factor for colonisation of FQ-R or ESBLproducing organisms. In our present study, data regarding the use of antibiotics during the preceding year were collected with a questionnaire. Most patients did not recall the specific name of the antibiotic used. As the study consent did not allow us to review study patients' antimicrobial prescriptions, the data on antimicrobial usage were based on the patients' recollections of their previous antimicrobial courses. Therefore, the previous use of antibiotics was analysed without dividing the antibiotics into different classes. As patients who have had previous biopsies during the last 6 months and/or had an acute prostatitis were excluded from the study, FQ exposure in other common indications (e.g. normal respiratory tract or soft tissue infections) amongst the study population can be assumed to be relatively low. Thus, the use of antibiotics in general, without dividing the antibiotics in to different classes, is not very informative approach for evaluating the risk of FQ-R in particular. However, the reduced risk of FQ resistance is not explicable in the present study.
In the present study, smoking history, age or diabetes had no significant impact on the risk of having FQ-R or 3GC-R strains. Although there are previous studies addressing this issue, the results are controversial. In pre-TRUS-Bx rectal swab samples, Taylor et al. [19] were unable to detect differences in FQ-R rates with age or diabetes. Tsu et al. [27] detected a statistically significant increase in E. coli antimicrobial resistance with diabetes but no correlation with age. Duplessis et al. [26] detected an increase in the FQ-R rate with age. These studies did not analyse smoking as a risk or preventive factor for antimicrobial resistance.
Our present study has several limitations. Firstly, our only source of data on risk factors was from patient questionnaire responses, which are susceptible to recall bias. In addition, we analysed recent antibiotic usage as a whole, without dividing into different antibiotic categories. Secondly, our study concentrated on the most common pathogen, E. coli, although it is not the only microorganism causing post-TRUS-Bx infectious complications. Thirdly, there are territorial differences in antibiotic susceptibility rates and 
Conclusion
FQ-R and/or 3GC-R (potentially ESBL-producing) intestinal E. coli strains in men undergoing TRUS-Bx in Finland is remarkable. The result is coherent with the global trend of increasing antimicrobial resistance. International travel appears to be an indisputable risk factor for having intestinal FQ-R E. coli strains. Contemporary antimicrobial resistance should be taken into account in the care of post-TRUS-Bx infections. Also, there may be a need for a reassessment of the antibiotic prophylaxis protocol in the TRUS-Bx procedure, particularly in certain at risk patients.
